Publications by authors named "Evan F Lind"

Claim this Profile
T
The aryl hydrocarbon receptor is associated with monocytic AML and innate immune resistance reversible with an AHR inhibitor.
Jennifer N Saultz, Daniel Bottomly, Faith Burns, Kaelan Byrd, Yoko Kosaka, Evan F Lind

Front Immunol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended exposure to low doses of azacitidine induces differentiation of leukemic stem cells through activation of myeloperoxidase.
Danny V Jeyaraju, Maryam Alapa, Ann Polonskaia, Alberto Risueño, Prakash Subramanyam, Evan F Lind

Haematologica· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leukemic mutation FLT3-ITD is retained in dendritic cells and disrupts their homeostasis leading to expanded Th17 frequency.
Patrick A Flynn, Mark D Long, Yoko Kosaka, Nicola Long, Jessica S Mulkey, Evan F Lind

Front Immunol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leukemic mutation FLT3-ITD is retained in dendritic cells and disrupts their homeostasis leading to expanded Th17 frequency.
Patrick A Flynn, Mark D Long, Yoko Kosaka, Jessica S Mulkey, Jesse L Coy, Evan F Lind

bioRxiv· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BET inhibitors rescue anti-PD1 resistance by enhancing TCF7 accessibility in leukemia-derived terminally exhausted CD8 T cells.
Kyle A Romine, Kevin MacPherson, Hyun-Jun Cho, Yoko Kosaka, Patrick A Flynn, Evan F Lind

Leukemia· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia.
Daniel Bottomly, Nicola Long, Anna Reister Schultz, Stephen E Kurtz, Cristina E Tognon, Evan F Lind

Cancer Cell· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunomodulatory effects of pevonedistat, a NEDD8-activating enzyme inhibitor, in chronic lymphocytic leukemia-derived T cells.
Scott Best, Vi Lam, Tingting Liu, Nur Bruss, Adam Kittai, Evan F Lind

Leukemia· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia.
Adam J Lamble, Yoko Kosaka, Ted Laderas, Allie Maffit, Andy Kaempf, Evan F Lind

Proc Natl Acad Sci U S A· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute myeloid leukemia-induced T-cell suppression can be reversed by inhibition of the MAPK pathway.
Kaycee B Moshofsky, Hyun J Cho, Guanming Wu, Kyle A Romine, Matthew T Newman, Evan F Lind

Blood Adv· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells.
David K Edwards, Kevin Watanabe-Smith, Angela Rofelty, Alisa Damnernsawad, Ted Laderas, Evan F Lind

Blood· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Timed Regulation of 3BP2 Induction Is Critical for Sustaining CD8 T Cell Expansion and Differentiation.
Ioannis D Dimitriou, Korris Lee, Itoro Akpan, Evan F Lind, Valarie A Barr

Cell Rep· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the Immune Microenvironment in Acute Myeloid Leukemia: A Focus on T Cell Immunity.
Adam J Lamble, Evan F Lind

Front Oncol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated functional and mass spectrometry-based flow cytometric phenotyping to describe the immune microenvironment in acute myeloid leukemia.
Adam J Lamble, Matthew Dietz, Ted Laderas, Shannon McWeeney, Evan F Lind

J Immunol Methods· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2.
Satoshi Inoue, Wanda Y Li, Alan Tseng, Isabel Beerman, Andrew J Elia, Evan F Lind

Cancer Cell· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
miR-155 Upregulation in Dendritic Cells Is Sufficient To Break Tolerance In Vivo by Negatively Regulating SHIP1.
Evan F Lind, Douglas G Millar, Dilan Dissanayake, Jonathan C Savage, Natasha K Grimshaw

J Immunol· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mir-155, a central modulator of T-cell responses.
Evan F Lind, Pamela S Ohashi

Eur J Immunol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Micro-RNA 155 is required for optimal CD8+ T cell responses to acute viral and intracellular bacterial challenges.
Evan F Lind, Alisha R Elford, Pamela S Ohashi

J Immunol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics.
Masato Sasaki, Christiane B Knobbe, Joshua C Munger, Evan F Lind, Dirk Brenner

Nature· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HUNK suppresses metastasis of basal type breast cancers by disrupting the interaction between PP2A and cofilin-1.
Miguel Quintela-Fandino, Enrico Arpaia, Dirk Brenner, Theo Goh, Faith Au Yeung, Evan F Lind

Proc Natl Acad Sci U S A· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nfil3/E4bp4 is required for the development and maturation of NK cells in vivo.
Shintaro Kamizono, Gordon S Duncan, Markus G Seidel, Akira Morimoto, Koichi Hamada, Evan F Lind

J Exp Med· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dendritic cells require the NF-kappaB2 pathway for cross-presentation of soluble antigens.
Evan F Lind, Cory L Ahonen, Anna Wasiuk, Yoko Kosaka, Burkhard Becher

J Immunol· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The in vivo function of a noncanonical TRAF2-binding domain in the C-terminus of CD40 in driving B-cell growth and differentiation.
Li-Fan Lu, Cory L Ahonen, Evan F Lind, Vanitha S Raman, W James Cook

Blood· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Strategies for selective priming of memory B cells.
Vanitha S Raman, Evan F Lind, Micah J Benson, Randolph J Noelle

Immunol Lett· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imprinting the fate of antigen-reactive B cells through the affinity of the B cell receptor.
Brian P O'Connor, Laura A Vogel, Weijun Zhang, William Loo, Danielle Shnider, Evan F Lind

J Immunol· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mast cells are essential intermediaries in regulatory T-cell tolerance.
Li-Fan Lu, Evan F Lind, David C Gondek, Kathy A Bennett, Michael W Gleeson

Nature· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis